Relmada Therapeutics Analyst Ratings
Relmada Therapeutics Analyst Ratings
| Date | Upside/Downside | Analyst Firm | Price Target Change | Rating Change | Previous / Current Rating |
|---|---|---|---|---|---|
| 01/23/2023 | 110.08% | SVB Leerink | $42 → $10 | Maintains | Outperform |
| 10/14/2022 | 68.07% | Goldman Sachs | → $8 | Downgrades | Buy → Neutral |
| 10/14/2022 | — | Guggenheim | Downgrades | Buy → Neutral | |
| 10/13/2022 | — | Oppenheimer | Downgrades | Outperform → Perform | |
| 09/23/2022 | 1601.68% | Goldman Sachs | $49 → $81 | Maintains | Buy |
| 09/06/2022 | 1160.5% | Guggenheim | $50 → $60 | Maintains | Buy |
| 05/09/2022 | 1244.54% | Oppenheimer | $75 → $64 | Maintains | Outperform |
| 03/24/2022 | 1013.45% | Goldman Sachs | $69 → $53 | Maintains | Buy |
| 12/20/2021 | 782.35% | SVB Leerink | $50 → $42 | Maintains | Outperform |
| 11/18/2021 | 950.42% | Mizuho | → $50 | Initiates Coverage On | → Buy |
| 10/28/2020 | 740.34% | Goldman Sachs | $69 → $40 | Downgrades | Buy → Neutral |
| 05/04/2020 | 1475.63% | SunTrust Robinson Humphrey | → $75 | Initiates Coverage On | → Buy |
| 04/21/2020 | 1223.53% | Goldman Sachs | → $63 | Initiates Coverage On | → Buy |
| 01/27/2020 | 1475.63% | Jefferies | → $75 | Initiates Coverage On | → Buy |
| 12/16/2019 | 1244.54% | Guggenheim | → $64 | Initiates Coverage On | → Buy |
| 日期 | 上行/下行 | 分析公司 | 目标价格变化 | 评级变化 | 上一次/当前评级 |
|---|---|---|---|---|---|
| 2023年1月23日 | 110.08% | SVB Leerink | $42→$10 | 维护 | 跑赢大盘 |
| 10/14/2022 | 68.07% | 高盛 | →$8 | 评级下调 | 购买→中性 |
| 10/14/2022 | - | 古根海姆 | 评级下调 | 购买→中性 | |
| 10/13/2022 | - | 奥本海默 | 评级下调 | 超越→表现 | |
| 09/23/2022 | 1601.68% | 高盛 | $49→$81 | 维护 | 买 |
| 09/06/2022 | 1160.5% | 古根海姆 | $50→$60 | 维护 | 买 |
| 05/09/2022 | 1244.54% | 奥本海默 | $75→$64 | 维护 | 跑赢大盘 |
| 03/24/2022 | 1013.45% | 高盛 | $69→$53 | 维护 | 买 |
| 12/20/2021 | 782.35% | SVB Leerink | $50→$42 | 维护 | 跑赢大盘 |
| 2021年11月18日 | 950.42% | 瑞穗 | →$50 | 开始承保 | →购买 |
| 10/28/2020 | 740.34% | 高盛 | $69→$40 | 评级下调 | 购买→中性 |
| 05/04/2020 | 1475.63% | SunTrust Robinson Humphrey | →$75 | 开始承保 | →购买 |
| 04/21/2020 | 1223.53% | 高盛 | →$63 | 开始承保 | →购买 |
| 2020/01/27 | 1475.63% | 杰富瑞 | →$75 | 开始承保 | →购买 |
| 2019年12月16日 | 1244.54% | 古根海姆 | →$64 | 开始承保 | →购买 |
What is the target price for Relmada Therapeutics (RLMD)?
瑞马达治疗公司(RLMD)的目标价格是多少？
The latest price target for Relmada Therapeutics (NASDAQ: RLMD) was reported by SVB Leerink on January 23, 2023. The analyst firm set a price target for $10.00 expecting RLMD to rise to within 12 months (a possible 110.08% upside). 8 analyst firms have reported ratings in the last year.
SVB Leerink于2023年1月23日报道了瑞玛达治疗公司(纳斯达克代码：RLMD)的最新目标价。这家分析公司将目标价定为10美元，预计RLMD将在12个月内升至(可能上涨110.08%)。去年有8家分析公司公布了评级。
What is the most recent analyst rating for Relmada Therapeutics (RLMD)?
瑞马达治疗公司(RLMD)的最新分析师评级是什么？
The latest analyst rating for Relmada Therapeutics (NASDAQ: RLMD) was provided by SVB Leerink, and Relmada Therapeutics maintained their outperform rating.
瑞马达治疗公司(纳斯达克代码：RLMD)的最新分析师评级由SVB Leerink提供，瑞马达治疗公司维持其表现优于大盘的评级。
When is the next analyst rating going to be posted or updated for Relmada Therapeutics (RLMD)?
Relmada治疗公司(RLMD)的下一次分析师评级将于何时发布或更新？
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Relmada Therapeutics, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Relmada Therapeutics was filed on January 23, 2023 so you should expect the next rating to be made available sometime around January 23, 2024.
分析师在进行了广泛的研究后得出股票评级，其中包括查阅公共财务报表，与Relmada Treeutics的高管和客户交谈，以及听取收益电话会议。大多数分析师每三个月就会这样做一次，所以你每年应该会得到每家公司每家公司的4个评级。Relmada治疗公司的上一次评级是在2023年1月23日提交的，所以你应该预计下一次评级将在2024年1月23日左右的某个时候提供。
Is the Analyst Rating Relmada Therapeutics (RLMD) correct?
分析师对Relmada Treeutics(RLMD)的评级正确吗？
While ratings are subjective and will change, the latest Relmada Therapeutics (RLMD) rating was a maintained with a price target of $42.00 to $10.00. The current price Relmada Therapeutics (RLMD) is trading at is $4.76, which is out of the analyst's predicted range.
虽然评级是主观的，并将发生变化，但最新的Relmada Treeutics(RLMD)评级保持不变，目标价在42.00美元至10.00美元之间。Relmada治疗公司(RLMD)目前的交易价格为4.76美元，超出了分析师的预测范围。